What is Agile Therapeutics Price-to-Operating-Cash-Flow?
As of today (2024-05-02), Agile Therapeutics's share price is $0.4395.
Agile Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.38. Hence, Agile Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .
The historical rank and industry rank for Agile Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:
Agile Therapeutics's Cash Flow from Operations per share for the
three
months ended in Dec. 2023 was $0.06.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-6.38.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 84.20% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 61.00% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 35.80% per year.
During the past 12 years, Agile Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 84.20% per year. The lowest was -10.20% per year. And the median was 20.40% per year.
Agile Therapeutics Price-to-Operating-Cash-Flow Historical Data
The historical data trend for Agile Therapeutics's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Agile Therapeutics Price-to-Operating-Cash-Flow Chart
|
Agile Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Price-to-Operating-Cash-Flow |
|
Get a 7-Day Free Trial
|
|
|
- |
- |
- |
- |
- |
|
Agile Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Price-to-Operating-Cash-Flow |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
- |
- |
- |
- |
- |
Competitive Comparison of Agile Therapeutics's Price-to-Operating-Cash-Flow
For the Drug Manufacturers - Specialty & Generic subindustry, Agile Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agile Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Agile Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Agile Therapeutics's Price-to-Operating-Cash-Flow falls into.
Agile Therapeutics Price-to-Operating-Cash-Flow Calculation
Agile Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as
| Price-to-Operating-Cash-Flow Ratio | = | Share Price | / | Cash Flow from Operations per share (TTM) |
| = | 0.4395 | / | -6.38 |
| = | |
Agile Therapeutics's Share Price of today is $0.4395.
Agile Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.38.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).
It can also be calculated from the numbers for the whole company:
Agile Therapeutics (Agile Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
500 College Road East, Suite 310, Princeton, NJ, USA, 08540
Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. The Company views its operations and manages its business in one operating and reporting segment, which is the business of commercializing its transdermal patch for use in contraception.
Executives
| Scott M Coiante |
officer: Chief Financial Officer |
101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540 |
| Josephine Torrente |
director |
101 POOR FARM ROAD, PRINCETON NY 08540 |
| Sandra Carson |
director |
C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540 |
| John W Hubbard |
director |
101 POOR FARM ROAD 3RD FLOOR, PRINCETON NJ 08540 |
| Fischer Seth H.z. |
director |
C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
| Sharon Surrey Barbari |
director |
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Amy Welsh |
officer: Chief Commercial Officer |
500 COLLEGE ROAD EAST, SUITE 310, C/O AGILE THERAPEUTICS, INC., PRINCETON NJ 08540 |
| Alfred Altomari |
director, officer: Chief Executive Officer |
C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540 |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Dennis Reilly |
officer: Chief Financial Officer |
600 COLLEGE ROAD EAST, PRINCETON NJ 08540 |
| Jason Butch |
officer: Principal Accounting Officer |
101 POOR FARM ROAD, PRINCETON NJ 08540 |
| Paul Korner |
officer: Sr. VP & Chief Medical Officer |
C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555 |
| Abhijeet J Lele |
director, See remarks |
C/O EP MEDYSTEMS, 575 RTE 73 N, WEST BERLIN NJ 08091 |
| Perceptive Advisors Llc |
10 percent owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Agile Therapeutics (Agile Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AGRX has been successfully added to your